• Nektar Therapeutics granted inducement equity awards to seven new hires on June 19, 2026 under its 2025 Inducement Plan.
• Awards comprised non-qualified stock options for 20,500 shares, alongside 3,900 restricted stock units.
• Options carry a $60.98 exercise price, matching the June 18, 2026 closing share price, with an eight-year term.
• Options vest over four years: 25% after one year, then monthly over three years; RSUs vest 25% after one year, then quarterly.
• The 2025 Inducement Plan was adopted on Nov. 6, 2025 for equity awards to newly hired employees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606261630PR_NEWS_USPR_____SF93422) on June 26, 2026, and is solely responsible for the information contained therein.